Dare Bioscience, Inc. (DARE) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $0.84. The rating moved from Neutral to Overbought on October 3, 2026.

• Public ratingOverbought (as of October 3, 2026)
• Last close$0.84
• Last changeMoved from Neutral to Overbought on October 3, 2026
• SectorHealthcare
• IndustryBiotechnology

See all overbought Healthcare stocks →

AI analysis

Dare Bioscience, Inc. is an early‑stage specialty biopharma with value concentrated in clinical programs and licensing potential. The company likely faces elevated funding pressure in the current risk‑off market, making near‑term dilution and liquidity the dominant drivers for equity holders. Material upside requires positive clinical/partnering news; absent that, downside from financing, trial setbacks, or payer/headwind compression is the more probable path over the coming month.

Key factors

• Early‑stage biopharma profile with limited or no meaningful commercial revenue; valuation driven by pipeline and clinical milestones
• High cash burn and likely need for near‑term financing or partnering to fund operations and trials
• Broad market risk‑off tone and cooling healthcare IPO/funding window reducing access to capital for small-cap device/biotech issuers
• Regulatory and clinical binary risk tied to trial readouts or approvals that would materially move value
• Competitive and payer pressures in the broader specialty pharma environment (pricing scrutiny, Medicare negotiation) that can reduce value of eventual approvals
• Potential upside catalysts include positive clinical data, licensing deals, or strategic partnerships

Risks

• Material dilution from follow-on financings if cash runway is short
• Clinical trial failure, delay or inconclusive data that would sharply reduce valuation
• Adverse regulatory outcomes or slower-than-expected regulatory timelines
• Weak investor appetite for small healthcare issuers in a risk‑off market, compressing secondary market liquidity and share price
• Downward pricing and access pressure from payer policy changes (e.g., drug pricing negotiations) that could diminish commercial prospects
• Operational execution risk (manufacturing, partner commercialization, or strategic missteps)

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.